Neurocysticercosis in Iran: An Unexpected Case and Literature Review


Neurocysticercosis is a significant public health issue worldwide. Even though cysticercosis was once thought to have been eradicated in the United States, it is currently a growing public health problem in the United States, and immigrants from endemic areas are at the highest risk of acquiring this disease. In Iran, there was no report from this worrisome infection. The clinical presentation of neurocysticercosis is variable and vague. In this article, we will explain a case of neurocysticercosis encountered in the Shohada Hospital pathology department, and then we will review neurologic and radiologic symptoms, laboratory and pathologic findings, as well as medication for treatment, briefly.

Share and Cite:

Z. Farahani, A. Moradi, A. Sedighi and M. Soleimani, "Neurocysticercosis in Iran: An Unexpected Case and Literature Review," Neuroscience and Medicine, Vol. 4 No. 4, 2013, pp. 189-193. doi: 10.4236/nm.2013.44030.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] M. Gemmell, Z. Matyas, Z. Pawlowsky and E. J. L. Soulsby, “Guidelines for Surveillance and Control of Taeniasis/Cysticercosis, Vol. 83,” World Health Organization, Switzerland, 1983, p. 49.
[2] G. Roman, J. Sotelo, O. Del Brutto, et al., “A Proposal to Declare Neurocysticercosis an International Reportable Disease,” Bulletin of the World Health Organization, Vol. 78, No. 3, 2000, pp. 399-406
[3] K. Hutcheson III, M. Kalafian, I. Taylor, J. Sagel and B. Clyburn, “Neurocysticercosis,” Southern Medical Journal, Vol. 7, 2000, pp. 666-668.
[4] M. T. Wallin and J. F. Kurtzke, “Neurocysticercosis in the United States: Review of an Important Emerging Infection,” Neurology, Vol. 63, No. 9, 2004, pp. 1559-1564.
[5] O. H. Del Brutto, J. Sotelo, “Neurocysticercosis: An Update,” Clinical Infectious Disease, Vol. 10, No. 6, 1988, pp. 1075-1087.
[6] J. G. Burneo, I. Plener and H. H. Garcia, “Neurocysticercosis in a Patient in Canada,” CMAJ, Vol. 180, No. 6, 2009, pp. 639-642.
[7] H. H. Garcia and O. H. Del Brutto “Neurocysticercosis: Updated Concepts about an Old Disease,” The Lancet Neurology, Vol. 4, No. 10, 2005, pp. 653-661.
[8] J. A. Serpa, L. S. Yancey and A. C. White Jr., “Advances in the Diagnosis and Management of Neurocysticercosis,” Expert Review of Anti-infective Therapy, Vol. 4, No. 6, 2006, pp. 1051-1061.
[9] H. H. Garcia, R. Gilman, M. Martinez, et al., “Cysticercosis as a Major Cause of Epilepsy in Peru. The Cysticercosis Working Group in Peru (CWG),” Lancet, Vol. 341, No. 8839, 1993, pp. 197-200.
[10] O. H. Del Brutto, V. Rajshekhar, A. C. White Jr., et al., “Proposed Diagnostic Criteria for Neurocysticercosis,” Neurology, Vol. 57, No. 2, 2001, pp. 177-183.
[11] J. A. Serpa, A. Moran, J. C. Goodman, T. P. Giordano, and A. C. White Jr, “Neurocysticercosis in the HIV Era: A Case Report and Review of the Literature,” American Journal of Tropical Medicine and Hygiene, Vol. 77, No. 1, 2007, pp. 113-117.
[12] S. Remy, MSN, RN, CEN and Vineland, “A 44-Year-Old Man with Neurocysticercosis,” Journal of Emergency Nursing, Vol. 35, No. 4, 2009, pp. 348-349.
[13] S. A. Cudlip, P. R. Wilkins and H. T. Marsh, “Endoscopic Removal of a Third Ventricular Cysticercal Cyst,” British Journal of Neurosurgery, Vol. 12, No. 5, 1998, pp. 452-454.
[14] R. Kelley, D. H. Duong and G. E. Locke, “Characteristics of Ventricular Shunt Malfunctions among Patients with Neurocysticercosis,” Neurosurgery, Vol. 50, No. 4, 2002, pp. 757-762.
[15] M. Bergsneider, L. T. Holly, J. H. Lee, W. A. King and J. G. Frazee, “Endoscopic Management of Cysticercal cysts within the Lateral and Third Ventricles,” Journal of Neurosurgery, Vol. 92, No. 1, 2000, pp. 14-23.
[16] V. Kalra, D. Mishra, A.Suri, R. Seth and A. Garg, “Intraventricular Neurocysticercosis,” The Indian Journal of Pediatrics, Vol. 76, No. 4, 2009, pp. 420-423.
[17] H. H. García, C. A. Evans, T. E. Nash, O. M. Takayanagui, A. C. White, D. Botero, V. Rajshekhar, V. C.Tsang, et al., “Current Consensus Guidelines for Treatment of Neurocysticercosis,” Clinical Microbiology Reviews, Vol. 15, No. 4, 2002, pp. 747-756.
[18] A. Escobar and K. M. Weidenheim, “The Pathology of Neurocysticercosis,” In: G. Singh and S. Prabhakar, Eds., Taenia solium Cysticercosis: From Basic to Clinical Science, United Kingdom CABI Publishing, Wallingford, 2002, pp. 289-305.
[19] A. C. White Jr., “Neurocysticercosis: Updates on Epidemiology, Pathogenesis, Diagnosis, and Management,” Annual Review of Medicine, Vol. 51, 2000, pp. 187-206.
[20] A. Carpio, “Neurocysticercosis: An Update,” The Lancet Infectious Diseases, Vol. 2, No. 12, 2002, pp. 751-762.
[21] M. P. Earnest, L. B. Reller, C. M. Filley and A. J. Grek, “Neurocysticercosis in the United States: 35 Cases and a Review,” Reviews of Infectious Diseases, Vol. 9, No. 5, 1987, pp. 961-979.
[22] J. E. Pittella, “Neurocysticercosis,” Brain Pathology, Vol. 7, No. 1, 1997, pp. 681-693.
[23] H. H. García, A. E. Gonzalez, C. A. Evans and R. H. Gilman, “Cysticercosis Working Group in Peru. Taenia solium Cysticercosis,” Lancet, Vol. 362, No. 9383, 2003, pp. 547-556.
[24] C. M. DeGiorgio, M. T. Medina, R. Durón , C. Zee and S. P. Escueta, “Neurocysticercosis,” Epilepsy Currents, Vol. 4, No. 3, 2004, pp. 107-111.
[25] D. Scharf, “Neurocysticercosis: Two Hundred Thirty-Eight Cases from a California Hospital,” Archives of Neurology, Vol. 45, No. 7, 1988, pp. 777-780.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.